Please assess the completion status of the following clinical trial:

Trial Title: Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented non-small cell carcinoma of the lung diagnosed within 16 weeks prior to study enrollment.~* Patient must be at least 18 years old at the time of consent.~* Stage III A or III B disease.~* Patients must be able to start study treatment within 6 weeks of study enrollment.~* Induction chemotherapy is allowed.~* Marginally resectable or unresectable at presentation.~* If the patient had exploratory thoracotomy, it must be done at least 3 weeks prior to enrollment.~Exclusion Criteria:~* Evidence of distant metastasis.~* Prior thoracic radiotherapy.~* Any history of allergic reaction to taxanes.~* Prior tumor resection. Candidate for upfront curative surgery.~* Pleural effusion visible on chest x-ray or the scout view of the CT chest.~* Unintentional weight loss within the month prior to diagnosis ≥ 10%.~* Previous or concomitant malignancy other than early stage tumor treated more than 3 years ago for cure.~* The presence of PET positive contralateral hilar disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET positive nodal disease measuring 15 mm or greater (Type: EXPERIMENTAL): Proton radiation with concomitant chemotherapy
- PET positive nodal disease measuring less than 15 mm (Type: EXPERIMENTAL): Proton radiation
- Patients considered resectable (Type: EXPERIMENTAL): Proton radiation plus surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).